MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$122.4K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Stock-based compensation
Accounts payable and accrued lia...
Net loss
Others
Negative Cash Flow Breakdown
Gain on derecognition of non-fin...
Change in fair value equity inve...
Prepaids and other current asset...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
341.011
-2,239.276
250,293.099
-1,114.369
Amortization of debt discount and deferred finance costs
156.431
145.583
62.48
54.478
Change in fair value of investment in gmp bio
-
-
365,346.775
-
Deferred income taxes
-
-
111,550
-
Stock-based compensation
730.41
1,641.847
2,195.094
183.742
Gain on derecognition of non-financial asset
1,100
-
-
-
Change in fair value equity investment
300
-
-
-
Loss on debt conversion
-
-
-1,058.976
-
Common shares issued to investors
0
130.766
-
-
Change in fair value of derivative
102.868
-90.08
320.8
-392.058
Accounts receivable
0
-49.266
-
-
Prepaids and other current assets
219.939
-5.34
18.75
-20.894
Accounts payable and accrued liabilities
402.245
-166.363
-256.854
155.661
Accounts payable to related party
0.513
0.514
0.513
0.514
Net cash used in operating activities
-92.197
-342.243
-783.017
-307.022
Proceeds from sales of common stock under equity purchase agreement
6.63
-
-
-
Net proceeds from convertible debt
150
350
0
478
Proceeds from short term loans, others
40.922
17
462.874
150
Repayment of short-term loans, others
-
50
-
-
Repaid to related party/others
32.955
-
-
-
Net cash provided by financing activities
214.597
317
462.874
628
Net increase in cash
122.4
-25.243
-320.143
320.978
Cash and restricted cash - beginning of period
83.614
108.857
429
106.128
Cash and restricted cash - end of period
206.014
83.614
108.857
429
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net proceeds from
convertible debt
$150K
something is missing
$50K
Proceeds from short term
loans, others
$40.922K
(-86.13%↓ Y/Y)
Proceeds from sales of
common stock under...
$6.63K
Net cash provided by
financing activities
$214.597K
(-27.26%↓ Y/Y)
Canceled cashflow
$32.955K
Net increase in cash
$122.4K
(6362.51%↑ Y/Y)
Canceled cashflow
$92.197K
Repaid to related
party/others
$32.955K
Stock-based compensation
$730.41K
Accounts payable and
accrued liabilities
$402.245K
(96.31%↑ Y/Y)
Net loss
$341.011K
(321.70%↑ Y/Y)
Amortization of debt discount
and deferred...
$156.431K
(92.90%↑ Y/Y)
Accounts payable to
related party
$0.513K
(-50.05%↓ Y/Y)
Net cash used in
operating activities
-$92.197K
(68.54%↑ Y/Y)
Canceled cashflow
$1,630.61K
Gain on
derecognition of...
$1,100K
Change in fair value
equity investment
$300K
Prepaids and other
current assets
$219.939K
(14690.79%↑ Y/Y)
Change in fair value of
derivative
$102.868K
(-75.79%↓ Y/Y)
Buy us a coffee
Oncotelic Therapeutics, Inc. (OTLC)
Oncotelic Therapeutics, Inc. (OTLC)